Biotech benefits as VC firms raise cash in Q2
This article was originally published in Scrip
US venture capital firms raised $10.3bn during the second quarter of 2015 – the highest quarterly total since the fourth quarter of 2007, according to the National Venture Capital Association (NVCA) – and roughly $2bn of the newly raised cash may be invested in biotechnology companies.
You may also be interested in...
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Newly renamed Flagship Pioneering has raised a $285m venture capital fund to remain invested in portfolio companies as they grow. Also, 12 new and growing biopharma companies raised $657.15m.
Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Biotech VC Funding Rises As Fewer Companies Get More Dollars
Public company valuations continue to slide as stock market investors shift priorities, but private biotechnology firms are attracting near record-breaking levels of venture capital with one pretty important caveat: More money is being invested in fewer US companies, especially at the earliest stages of business formation.